Compare Citius Pharmaceuticals Inc (CTXR) vs Invesco DB Commodity Index Tracking Fund (DBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Invesco DB Commodity Index Tracking Fund — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while Invesco DB Commodity Index Tracking Fund trades at $30.12. The key difference: Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | DBC | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $1.82 | $31.69 |
52-Week Low | $0.48 | $21.62 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
DBC trades at $30.07, up 0.47% today, with a bullish technical signal driven by moving averages. The stock shows neutral oscillators and key support/resistance clustered around $30. Recent news highlights commodities ETFs gaining attention as inflation hedges, with articles discussing broad commodity exposure and geopolitical impacts on markets.
The outlook for DBC is cautiously optimistic, supported by technical momentum and growing investor interest in commodities for diversification. Risks include commodity price volatility and geopolitical tensions, but the current trend suggests potential for upward movement if broader market conditions remain favorable.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →
